Sign in

CIK 0001651308 · Large accelerated filer

BeOne Medicines Ltd.

Sign in to watch
Ticker
BEIGF
Exchange
Nasdaq, OTC
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
operating
EIN
981209416
Phone
41-616851900
Business address
C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
Former names
BeiGene, Ltd.

Securities

  • ONC American Depositary Shares Nasdaq
  • BEIGF Common stock OTC
  1. 8-K Event Results of operations
  2. 4 Planned sale SVP, General Counsel sold 332 shares at $311.59 ($103,448)
  3. 4 Planned sale SVP, General Counsel sold 341 shares at $300.00 ($102,300)
  4. 4 Grant or award Chief Executive Officer acquired 444,912 shares (grant or award)
  5. 4 Grant or award SVP, General Counsel acquired 95,264 shares (grant or award)
  6. 4 Grant or award President, Global Head of R&D acquired 167,635 shares (grant or award)
  7. 4 Grant or award President and COO acquired 247,546 shares (grant or award)
  8. 4 Grant or award Chief Financial Officer acquired 119,587 shares (grant or award)
  9. 10-K Report Annual Report
  10. 8-K Event Results of operations
  11. 4 Planned sale SVP, General Counsel sold 1,660 shares at an average $349.52 ($580,197)
  12. 144 Insider Sale of Securities
  13. 4 Planned sale SVP, General Counsel sold 664 shares at $331.76 ($220,289)
  14. 4 Grant or award President, Global Head of R&D acquired 427,895 shares (grant or award)
  15. 8-K Event Agreement ended
  16. 8-K Event Executive or director change
  17. 4 Planned sale Chief Executive Officer sold 100,000 shares at an average $306.59 ($30,659,419)
  18. 144 Insider Sale of Securities
  19. 4 Planned sale SVP, General Counsel sold 664 shares at an average $321.64 ($213,569)
  20. 4 Open-market sale Director sold 2,627 shares at an average $340.90 ($895,534)

Page 7 of 64 · 1,278 filings